This guideline serves as a reference for the multiple activities related to operating a tandem mass spectrometry laboratory as part of public and private newborn screening programs.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.
Newborn Screening by Tandem Mass Spectrometry

Víctor R. De Jesús, PhD
Mark A. Morrissey, PhD
Donald H. Chace, PhD, MSFS, FACB
Uttam Garg, PhD, DABCC
W. Harry Hannon, PhD
Christopher A. Haynes, PhD
Patricia Hunt
David Kasper, PhD
Mark Kuracina, MBA, BSc
Giancarlo la Marca, Pharm Sc
Adrienne Manning
Mary A. Seeterlin, PhD
Dianne R. Webster, PhD, FHGSA
Ronald J. Whitley, PhD, DABCC, FACB
William W. Wood, PhD
Raquel Yahyaoui, MD, PhD

Abstract

Clinical and Laboratory Standards Institute guideline NBS04—Newborn Screening by Tandem Mass Spectrometry describes best practice procedures for specimen and reagent preparation, instrument and analyte calibration, method validation, QA and QC, run acceptance criteria with multianalyte platforms, external treatment effects on test results (eg, transfusions and total parenteral nutrition), results interpretation and reporting, follow-up recommendations, and the use of tandem mass spectrometry for second-tier testing.


The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If you or your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail: customerservice@clsi.org. Website: www.clsi.org.
# Contents

Abstract .................................................................................................................................................... i

Committee Membership ........................................................................................................................ iii

Foreword .............................................................................................................................................. vii

Chapter 1: Introduction ....................................................................................................................... 1
  1.1 Scope ........................................................................................................................................ 1
  1.2 Background ............................................................................................................................ 1
  1.3 Standard Precautions ........................................................................................................... 2
  1.4 Terminology ........................................................................................................................... 2

Chapter 2: Overview of Newborn Screening by Tandem Mass Spectrometry ................................... 9
  2.1 Newborn Screening by Tandem Mass Spectrometry Processes ........................................... 9
  2.2 Path of Workflow .................................................................................................................... 9

Chapter 3: Reagents, Internal Standards, and Sample Preparation ................................................... 11
  3.1 Preparing the Reagents ....................................................................................................... 11
  3.2 Selecting Stable Isotopes: Labeled Internal Standards ...................................................... 12
  3.3 Preparing the Sample ......................................................................................................... 13

Chapter 4: Mass Spectrometer Instrument Considerations ............................................................... 19
  4.1 Selecting the Instrument, Process, and Software ............................................................ 19
  4.2 Choosing Data Acquisition Modes (Full-Scan Acquisition Mode vs Selected Reaction Monitoring) ................................................................................................................. 21
  4.3 Calibrating and Verifying the Mass Spectrometer .............................................................. 23
  4.4 Calculating Results (Quantitation) ..................................................................................... 24
  4.5 Operating and Maintaining the Instrument ...................................................................... 25
  4.6 Method Verification and Validation ................................................................................... 31

Chapter 5: Sample Analysis for Newborn Screening Disorders ....................................................... 37
  5.1 Establishing and Validating Cutoffs ................................................................................... 37
  5.2 Quality Assurance and Quality Control ............................................................................ 39
  5.3 Proficiency Testing ............................................................................................................. 41
  5.4 Result Run Acceptance Criteria ...................................................................................... 42
  5.5 Additional Assays ............................................................................................................... 43

Chapter 6: Result Interpretation and Reporting ................................................................................ 49
  6.1 Interpreting Results ............................................................................................................. 49
  6.2 Evaluating External Sources of Error .............................................................................. 55
  6.3 Reporting Results ............................................................................................................... 56
  6.4 Initiating Short-Term Follow-up Activities .................................................................... 57

Chapter 7: Conclusion ....................................................................................................................... 58

Chapter 8: Supplemental Information ............................................................................................... 58

References ............................................................................................................................................ 59

Appendix A. Common Metabolic Disorders: Organic Acid Disorders, Fatty Acid Oxidation Disorders, and Aminoacidopathies .......................................................... 65

Appendix B. Metabolites Measured by Tandem Mass Spectrometry: Amino Acids ...................... 69

Appendix C. Metabolites Measured by Tandem Mass Spectrometry: Acylcarnitines ................. 70
Contents (Continued)

Appendix D. Preparation of Extraction Solution ................................................................. 72
Appendix E. Scan Speed Consideration .............................................................................. 75
Appendix F. In-House Control Preparation .......................................................................... 78
Appendix G. Flow Path Blockages ..................................................................................... 80
Appendix H. Tubing Considerations .................................................................................. 82
Appendix I. Troubleshooting Guides ................................................................................ 85
Appendix J. Non-Recommended Tandem Mass Spectrometry Assays ............................... 87
The Quality Management System Approach .................................................................... 92
Related CLSI Reference Materials ................................................................................... 94
Foreword

Nearly 10 million newborns worldwide are screened annually for metabolic and genetic disorders. The goal of these newborn screening (NBS) tests is early diagnosis and treatment that will likely prevent or reduce the severe medical outcomes that occur in undiagnosed or untreated infants. The number of disorders screened from a newborn’s dried blood spot (DBS) specimen has increased significantly in the last two decades. The essential methods for detecting fatty acylcarnitines and amino acids from DBS using tandem mass spectrometry (MS/MS) were developed in the early 1990s and put into clinical practice by private and academic laboratories in the mid-1990s. By 2000, MS/MS analysis of these metabolites had been adopted for use in three public health laboratories in the United States, and was well underway in Australia. It has now expanded to almost all screening programs worldwide. The number of disorders detectable by MS/MS depends on how the analysis is performed. In its original configuration, the method could detect more than 60 biomarkers, and each biomarker could detect one or more disorders. The exact number of disorders that are reported is often debated because it relies on the number of metabolites measured, data interpretation, the way disorders are counted, and public policy. In the United States, the Recommended Uniform Screening Panel (RUSP) was first accepted for NBS programs on May 21, 2010. Today, the RUSP identifies 34 core conditions and 26 secondary conditions, of which 43 are detected primarily by MS/MS analysis.

MS/MS is a fundamentally different technology than systems previously used by most NBS laboratories. It is a versatile and complex system that can be easily adapted to the users’ preferred testing approach. This led to numerous variations in NBS by MS/MS, and it became challenging to compare results between laboratories. There is a recognized need to develop consensus solutions to provide more consistency between MS/MS screening programs. There have been numerous workshops, training courses, and publications since the first US workgroup report, with many methodological issues remaining unresolved. Variations of the original method include specimen and reagent preparation, instrument and analyte calibration, method validation, QA and QC, run acceptance criteria with multianalyte platforms, external treatment effects on test results (e.g., transfusions and total parenteral nutrition), results interpretation and reporting, and follow-up recommendations. In addition to MS/MS being used as the primary screening method, the use of this technology as a second-tier test has been introduced to improve other NBS test sensitivity and specificity. A consensus guideline developed by experts for using MS/MS in NBS will ensure that babies tested using MS/MS have the opportunity to get equivalent screening services throughout the world.

Overview of Changes

This guideline replaces the previous edition of the guideline, NBS04-A, published in 2010. Several changes were made in this edition, including:

- Reorganization to follow the path of workflow
- Updating methodology and references throughout the guideline
- Removing mass spectrometer setup instructions for m/z peak resolution (Subchapter 4.5.4.1) and providing the reference
- Updating terminology throughout the guideline

NOTE: The content of this guideline is supported by the CLSI consensus process, and does not necessarily reflect the views of any single individual or organization.
NBS04, 2nd ed.

Key Words

Acylcarnitines, amino acids, cutoffs, dried blood spot, newborn screening, second-tier testing, tandem mass spectrometry
Newborn Screening by Tandem Mass Spectrometry

Chapter 1: Introduction

This chapter includes:

- Guideline’s scope and applicable exclusions
- Background information pertinent to the guideline’s content
- Standard precautions information
- “Note on Terminology” that highlights particular use and/or variation in use of terms and/or definitions
- Terms and definitions used in the guideline
- Abbreviations and acronyms used in the guideline

1.1 Scope

This guideline is intended to assist newborn screening (NBS) laboratory personnel in the routine use of tandem mass spectrometry (MS/MS) for the detection of metabolites that may indicate certain metabolic disorders using dried blood spot (DBS) specimens. The guideline describes:

- Preparation procedures for reagents, specimens, standards, and controls
- Calibration (both instrument and analyte)
- Standardization
- Control acceptance criteria
- Disorder profiles (interpretation of MS/MS spectra)
- External effects on results (e.g., transfusion and total parenteral nutrition [TPN])
- Results reporting
- Second-tier testing
- Follow-up recommendations

This guideline:

- Is not intended to provide general information for screening on all conditions, only screening information related to MS/MS
- Does not cover confirmatory or diagnostic testing

1.2 Background

The goal of NBS is early detection of babies at increased risk for selected heritable disorders so that diagnostic testing, clinical evaluation, and, if necessary, medical treatment can be initiated promptly. The first DBS NBS began in the 1960s with the introduction of a bacterial inhibition assay for phenylketonuria (PKU). Because it was reliable, simple, inexpensive, and could be scaled for large numbers of specimens,
the test was suitable for population screening. In addition, the method used DBS specimens, a simple and efficient method for collecting and transporting blood specimens.

NBS programs expanded as additional bacterial inhibition assays and other technologies (eg, immunochemistry and electrophoresis) were developed, laboratories screened for more disorders, and the number of babies screened increased. A significant addition was the introduction of MS/MS to the NBS laboratory. Because MS/MS is a multiplex method that measures several analytes on the same sample simultaneously, it is possible to detect multiple disorders on the same testing platform.

The current list of common metabolic disorders detectable by routine screening on MS/MS is provided in Appendix A. They are organic acid disorders (Table A1), fatty acid oxidation (FAO) disorders (Table A2), and aminoacidopathies (Table A3). The current list of metabolites that may be measured to detect common metabolic disorders is provided in Appendix B for amino acids and Appendix C for acylcarnitines.

1.3 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of bloodborne pathogens. Published guidelines are available that discuss the daily operations of diagnostic medicine in humans and animals while encouraging a culture of safety in the laboratory. For specific precautions for preventing the laboratory transmission of all known infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all known infectious diseases, refer to CLSI document M29.

1.4 Terminology

1.4.1 A Note on Terminology

CLSI, as a global leader in standardization, is firmly committed to achieving global harmonization whenever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrological community have evolved differently in different countries and regions, and that legally required use of terms, regional usage, and different consensus timelines are all important considerations in the harmonization process. CLSI recognizes its important role in these efforts, and its consensus process focuses on harmonization of terms to facilitate the global application of standards and guidelines.

NOTE: Mandates are generally reserved for CLSI standards, but are occasionally allowed in CLSI guidelines. In CLSI guidelines, use of the term “must” is either 1) based on a requirement or 2) indicative of a necessary step to ensure patient safety or proper fulfillment of a procedure. The document development committee evaluated use of the term “must” and deemed it appropriate.

CLSI uses the globally applicable terms preexamination, examination, and postexamination in its documents. However, in the NBS laboratory, DBS specimens are examined to ensure they are satisfactory before they are “analyzed.” Hence, for the purposes of CLSI NBS documents, the terms preanalytical, analytical, and postanalytical are used in place of preexamination, examination, and postexamination. Additionally, the term analysis is used in place of examination. Although contradictions among these terms may exist between new CLSI NBS documents and already published NBS documents, these contradictions will be reconciled as documents go through the routine revision process.
The Quality Management System Approach

Clinical and Laboratory Standards Institute (CLSI) subscribes to a quality management system (QMS) approach in the development of standards and guidelines, which facilitates project management; defines a document structure using a template; and provides a process to identify needed documents. The QMS approach applies a core set of “quality system essentials” (QSEs), basic to any organization, to all operations in any health care service’s path of workflow (ie, operational aspects that define how a particular product or service is provided). The QSEs provide the framework for delivery of any type of product or service, serving as a manager’s guide. The QSEs are as follows:

- Organization
- Customer Focus
- Facilities and Safety
- Personnel
- Purchasing and Inventory
- Process Management
- Documents and Records
- Information Management
- Nonconforming Event Management
- Assessments
- Continual Improvement

NBS04 covers the QSEs indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section.

<table>
<thead>
<tr>
<th>Organization</th>
<th>Customer Focus</th>
<th>Facilities and Safety</th>
<th>Personnel</th>
<th>Purchasing and Inventory</th>
<th>Equipment</th>
<th>Process Management</th>
<th>Documents and Records</th>
<th>Information Management</th>
<th>Nonconforming Event Management</th>
<th>Assessments</th>
<th>Continual Improvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EP05</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C62</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EP06</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP07</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EP07</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP09</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EP10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EP14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EP15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EP17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EP19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EP19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EP19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP21</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EP21</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP31</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EP31</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M29</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EP10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NBS01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EP19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NB501</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EP19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NB502</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EP19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NB503</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EP19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NB506</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EP19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QBS01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>QBS01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QBS02</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>QBS01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QBS03</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>QBS01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QBS06</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>QBS01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QBS24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>QBS01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QBS01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>QBS01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QBS01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>QBS01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QBS24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>QBS01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QBS24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>QBS01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

©Clinical and Laboratory Standards Institute. All rights reserved.
Path of Workflow

A path of workflow is the description of the necessary processes to deliver the particular product or service that the organization or entity provides. A laboratory path of workflow consists of the sequential processes: preexamination, examination, and postexamination (see Subchapter 1.4.1 for newborn screening laboratories) and their respective sequential subprocesses. All laboratories follow these processes to deliver the laboratory’s services, namely quality laboratory information.

NBS04 covers the medical laboratory path of workflow processes indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section.
Explore the Latest Offerings From CLSI!

As we continue to set the global standard for quality in laboratory testing, we are adding products and programs to bring even more value to our members and customers.

By becoming a CLSI member, your laboratory will join 1,600+ other influential organizations all working together to further CLSI’s efforts to improve health care outcomes. You can play an active role in raising global laboratory testing standards—in your laboratory, and around the world.

Find out which membership option is best for you at [www.clsi.org/membership](http://www.clsi.org/membership).

Find what your laboratory needs to succeed! CLSI U provides convenient, cost-effective continuing education and training resources to help you advance your professional development. We have a variety of easy-to-use, online educational resources that make eLearning stress-free and convenient for you and your staff.

See our current educational offerings at [www.clsi.org/education](http://www.clsi.org/education).

When laboratory testing quality is critical, standards are needed and there is no time to waste. eCLIPSE™ Ultimate Access, our cloud-based online portal of the complete library of CLSI standards, makes it easy to quickly find the CLSI resources you need.

Learn more and purchase eCLIPSE at [clsi.org/eCLIPSE](http://clsi.org/eCLIPSE).

For more information, visit [www.clsi.org](http://www.clsi.org) today.